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new Synthetic opioids (nSos) are one class of new psychoactive Substances (npS) enjoying 
increasing popularity in Europe. Data on their toxicological or metabolic properties have not yet 
been published for most of them. In this context, the metabolic fate of three NSOs, namely, trans-
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzenacetamide (U-51754), trans-4-
bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (U-47931E), and 2-methoxy-N-
phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide (methoxyacetylfentanyl), was elucidated by 
liquid chromatography high-resolution mass spectrometry after pooled human S9 fraction (phS9) 
incubations and in rat urine after oral administration. The following major reactions were observed: 
demethylation of the amine moiety for U-51754 and U-47931E, N-hydroxylation of the hexyl ring, 
and combinations thereof. N-dealkylation, O-demethylation, and hydroxylation at the alkyl part for 
methoxyacetylfentanyl. Except for U-47931E, parent compounds could only be found in trace amounts 
in rat urine. Therefore, urinary markers should preferably be metabolites, namely, the N-demethyl-
hydroxy and the hydroxy metabolite for U-51754, the N-demethylated metabolite for U-47931E, 
and the N-dealkylated metabolite as well as the O-demethylated one for methoxyacetylfentanyl. In 
general, metabolite formation was comparable in vitro and in vivo, but fewer metabolites, particularly 
those after multiple reaction steps and phase II conjugates, were found in phS9. These results were 
consistent with those of comparable compounds obtained from human liver microsomes, human 
hepatocytes, and/or human case studies.
There has been a rapid increase in New Psychoactive Substances (NPS) over the last decade. Many of them are not 
yet controlled and predominantly sold via the Internet as ‘legal’ replacements for drugs already subject to con-
trols, such as heroin, cannabis or cocaine. New Synthetic Opioids (NSOs) are one class of NPS, mostly consisting 
of analogues of the highly potent analgesic fentanyl exploiting the fentanyl phenylpiperidine structure1. There 
are also other non-fentanyl synthetic opioids that share neither the fentanyl-like nor the classical morphine-like 
chemical structure. In Europe, their availability and popularity has grown continuously over recent years2. NSOs 
include compounds that were produced by pharmaceutical companies looking for new pharmaceutics, but were 
never registered for medical use due to strong side effects or insufficient action. Furthermore, NSOs are illegally 
synthesised in clandestine laboratories in China through modification of molecule residues3–6. Multiple cases of 
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classical opioid toxidrome and several overdose deaths in Europe related to NSOs have been reported in recent 
years3,7–10. On the one hand, users are often not aware of consuming these compounds, because batches might 
be sold as heroin, other illicit opioids or even as counterfeit pain killers3,11. On the other, only little is known and 
published about the toxicology of these substances12.
Two non-fentanyl-related compounds discussed in drug user forums and available for sale on the Internet 
are trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzenacetamide (U-51754) and trans-
4-bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (U-47931E, bromadoline). Both are structur-
ally related to 3,4-dichloro-N-[(1 R,2 R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide, commonly known 
as U-47700, and were synthesised by the Upjohn Company in an attempt to produce non-addicting analgesics 
as potent as morphine. Oral doses for U-51754 range from 12 to 25 mg and for U-47931E from 25 to 50 mg13–15. 
Despite being discussed in drug user forums since U-47700 was subjected to controls, both compounds have not 
been detected in forensic or clinical samples so far16, which may be due to the lack of information about suitable 
urine screening targets.
Another NSO, a fentanyl analogue, which has been associated with several fatal intoxications, is 
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide, commonly known as methoxyacetylfen-
tanyl17. So far, fatalities in Sweden, Denmark, and the USA have been reported, together with numerous seizures 
throughout Europe18. According to drug user forums, the ingested dose of methoxyacetylfentanyl ranges from 0.5 
to 5 mg depending on the route of administration19,20. However, no reports regarding potency are available yet17,18.
To understand and monitor intoxications with NSOs, knowledge of analytical targets is necessary for toxi-
cological analysis. As urine is the preferred matrix for comprehensive screening, e.g. in abstinence monitoring 
programmes, doping analysis, workspace drug testing, and in the case of suspected intoxications, metabolites 
should be known.
Owing to the lack of such data, the aim of the present work was to elucidate the metabolic patterns of the 
synthetic non-fentanyl opioids U-51754 and U-47931E and of methoxyacetylfentanyl by using liquid chroma-
tography high-resolution tandem mass spectrometry (LC-HR-MS/MS). Metabolic identification was performed 
in vitro using pooled human S9 fractions (phS9) and in vivo analysing rat urine after oral administration. Finally, 
both models were compared.
experimental
Chemicals and reagents. Methoxyacetylfentanyl hydrochloride (purity ≥ 98%), U-51754 hydrochlo-
ride (purity 98%), and U-47931E were purchased from LGC Standards (Wesel, Germany). Isocitrate, isocitrate 
dehydrogenase, superoxide dismutase, 3′-phosphoadenosine-5′-phosphosulfate (PAPS), S-(5′-adenosyl)-L-
methionine (SAM), dithiothreitol (DTT), reduced glutathione (GSH), acetyl carnitine, and acetyl coenzyme A 
(AcCoA) were all purchased from Sigma (Taufkirchen, Germany), NADP+ from Biomol (Hamburg, Germany), 
and acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid (LC-MS grade), methanol 
(LC-MS grade), glucuronidase (EC No. 3.2.1.32)/arylsulfatase (EC No. 3.1.6.1) from Helix pomatia L, and all 
other chemicals and reagents (analytical grade) from VWR (Darmstadt, Germany). phS9 (20 mg protein/mL, 
from 30 individual donors), UGT reaction mix solution A (25 mM UDP-glucuronic acid), and UGT reaction 
mix solution B (250 mM Tris–HCl, 40 mM MgCl2, and 0.125 mg/mL alamethicin) were obtained from Corning 
(Amsterdam, The Netherlands). After delivery, the enzyme preparations were thawed at 37 °C, aliquoted, 
snap-frozen in liquid nitrogen, and stored at −80 °C until use.
Incubation conditions for identification of phase I and II metabolites by LC-HR-MS/MS in phS9. 
The incubation conditions were in accordance to the experimental design developed by Richter et al.21. 
Incubations of phS9 (final protein concentration of 2 mg/mL) were performed after 10 min pre-incubation at 
37 °C with 25 μg/mL alamethicin (UGT reaction mix solution B), 90 mM phosphate buffer (pH 7.4), 2.5 mM 
Mg2+, 2.5 mM isocitrate, 0.6 mM NADP+, 0.8 U/mL isocitrate dehydrogenase, 100 U/mL superoxide dismu-
tase, 0.1 mM AcCoA, and 2.3 mM acetyl carnitine. Afterwards, to reach a final volume of incubation mixture 
of 150 µL, 2.5 mM UDP-glucuronic acid (UGT reaction mix solution A), 40 μM aqueous PAPS, 1.2 mM SAM, 
1 mM DTT, 10 mM GSH, and 25 μM substrate in phosphate buffer were added. All given concentrations are final 
concentrations. By adding the substrate, the reaction was initiated and the mixture was incubated for 60 and 
360 min respectively. After 60 min a 60 µL aliquot of the mixture was transferred into a reaction tube. Reactions 
were terminated by adding 20 µL of ice-cold acetonitrile. The remaining mixture was incubated for additional 
5 h. Thereafter, the reactions were stopped by adding 30 µL of ice-cold acetonitrile. The solutions were cooled 
for 30 min at −18 °C and centrifuged for 2 min at 14,000 rpm. The supernatants were transferred into autosam-
pler vials and 5 µL injected onto the Orbitrap-based LC-HR-MS/MS system as described below. To confirm the 
absence of interfering compounds and to identify non-metabolically originated compounds, additional blank 
incubations without substrate and control samples without phS9 were prepared.
Rat urine samples. According to an established study design22–24, the investigations were performed using 
rat urine samples from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological diagnostic rea-
sons according to German law. The experimental protocol was approved by an ethics committee (Landesamt für 
Verbraucherschutz, Saarbrücken, Germany). For metabolite identification, the compounds were administered in 
an aqueous suspension by gastric intubation of a single 0.6 mg/kg (U-47931E, U-51754) or 0.06 mg/kg (methoxy-
acetylfentanyl) body weight dose, calculated based on doses reported in trip reports and scaled by dose-by-factor 
approach from man to rat according to Sharma and McNeill16. The rats were housed in metabolism cages for 24 h, 
having water ad libitum. Urine was collected separately from faeces over a 24 h period using a grid plate. Blank 
urine samples were collected before drug administration to verify that the samples were free of interfering com-
pounds. The samples were aliquoted and stored at −20 °C before analysis.
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Sample preparation for identification of phase I and II metabolites by LC-HR-MS/MS in rat urine. 
In accordance to published procedures25, 100 µL of urine was mixed with 500 µL of acetonitrile for precipitation. 
After shaking and centrifugation for 2 min at 14,000 rpm, the supernatant was transferred into new vials and gen-
tly evaporated to dryness under a stream of nitrogen. Afterwards, the extract was reconstituted in 50 µL of eluent 
A and eluent B (1:1, v/v) and transferred into autosampler vials.
According to previous studies26, additionally, urine samples were treated with β-glucuronidase/arylsulfatase 
for conjugate cleavage prior to the extraction procedure. A volume of 200 µL urine was incubated with 20 µL 
β-glucuronidase/arylsulfatase and 180 µL 100 mM aqueous ammoniumacetate buffer (pH 5.2) for 2 h at 55 °C. 
The extract was precipitated by adding 1 mL of acetonitrile and stored for 5 min at −20 °C. After shaking and 
centrifugation, the supernatant was gently evaporated and reconstituted with 100 µL of mobile phase A and B 
(1:1, v/v) described below.
Furthermore, a basic solid phase extraction (SPE) was performed23. SPE was carried out using Biotage HCX 
columns (Isolute Confirm HXC cartridges, 130 mg, 3 mL from Biotage, Uppsala, Sweden). They were conditioned 
with 1 mL of methanol and 1 mL of water. An aliquot of 2.5 mL urine was mixed with 2 mL of water and 50 µL of 
internal standard (0.01 mg/mL trimipramine-d3) and loaded onto the cartridges. Two washing steps with 1 mL 
water and 1 mL HCl (0.01 M) were performed. Maximum vacuum was applied for a short time. After adding 2 mL 
of methanol, the columns were dried for one min under maximum vacuum. Analyte elution was performed with 
1 mL methanol/33% aqueous ammonia (98:2 v/v). The eluate was evaporated to dryness under a gentle stream 
of nitrogen at 70 °C and reconstituted with 50 µL of methanol. For conjugate cleavage, additional urine aliquots 
were treated with glucuronidase/arylsulfatase prior to the extraction procedure. An aliquot of 2.5 mL urine was 
adjusted to pH 5.2 with 1 M acetic acid. After incubation with 50 µL glucuronidase/arylsulfatase for 2 h at 55 °C 
following centrifugation, SPE was performed as described above. Five microlitres of the extracts were injected 
onto the LC-HR-MS/MS system with conditions described below.
LC-HR-MS/MS instrumentation for identification of phase I and II metabolites. As described 
previously27, the extracts were analysed using a Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex 
UltiMate 3000 RS pump consisting of a degaser, a quaternary pump, and an UltiMate autosampler, coupled to a 
TF Q-Exactive Plus system equipped with a heated electrospray ionization (HESI)-II source.
The LC conditions were as follows: Gradient elution was run on a TF Accucore PhenylHexyl column 
(100 mm × 2.1 mm, 2.6 µm) with column oven temperature of 60 °C. The mobile phase consisted of 2 mM aque-
ous ammonium formate containing 0.1% (v/v) formic acid and 1% (v/v) acetonitrile (pH 3, eluent A), and 2 mM 
ammonium formate solution with acetonitrile/methanol (50:50, v/v) containing 0.1% (v/v) formic acid and 1% 
(v/v) water (eluent B). The gradient and flow rate were programmed as follows: 0–1 min hold 99% A, 1–10 min 
99% A to 1% A, both with flow rate 0.5 mL/min, 10–11.5 min hold, 11.5–13.5 min hold 99% A, both with flow 
rate 0.8 mL/min.
The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; spray 
voltage, 3.00 kV; heater temperature, 320 °C; ion transfer capillary temperature, 320 °C; and S-lense RF level, 60.0.
The mass spectrometry was operated in positive ionisation mode using full scan (FS) and subsequent data 
dependent acquisition (DDA) mode with inclusion list containing the m/z values of expected metabolites. Mass 
calibration was done prior to analysis according to the manufacture’s recommendations using external mass cali-
brators. The settings for FS data were as follows: resolution, 35,000; microscans, 1; automatic gain control (AGC) 
target, 1e6; maximum injection time (IT), 120 ms; scan range for U-compounds, m/z 100–600 and for methoxy-
acetylfentanyl, m/z 180–600. The settings for the DDA mode were as follows: option “do not pick others”, enabled; 
dynamic exclusion, off; resolution, 17,500; microscans, 1; loop count, 5; AGC target, 2e5; maximum IT, 250 ms; 
isolation window, 1.0 m/z, high collision dissociation (HCD) with stepped normalised collision energy (NCE), 
17.5, 35, and 52.5%; spectrum data type, profile; underfill ratio, 0.5%. For data handling Xcalibur Qual Browser 
software version 3.0.63 was used. The MS settings as well as the LC conditions were the same for analysing all 
samples.
Results
eSi+ HR-MS/MS of the investigated compounds and tentative identification of their phase I 
metabolites based on MS/MS fragmentation. An overview of all tentatively identified phase I and II 
metabolites is given in Tables 1–3, including elemental compositions, exact masses, accurate masses, character-
istic fragment ions, mass errors, and retention times. Selected ESI+ MS2 spectra of the most abundant metabo-
lites are shown in Figs 1–3. Selected mass spectral data for additional metabolites are shown in the Electronic 
Supplementary Material (EMS). Owing to the high number of tentatively identified metabolites, not all are dis-
cussed in detail in the following. The numbering of given examples is in accordance with the respective tables.
As already described for U-47700 in previous metabolism studies28, the HR-MS data indicated that U-51754 
and U-47931E could be broken down into two parts at the amide nitrogen usually forming fragment ions that 
belong to the dichlorophenyl-N-methylacetamide part or the cyclohexyl part. The fragment ions of the unmod-
ified or modified dichlorophenyl part or the cyclohexyl part were used (according to Figs 1 and 2 and Tables 1 
and 2) for the spectra interpretation and identification of the expected metabolites based on the accurate pre-
cursor mass (PM) and calculated molecular formulas. Based on the procedure described, 14 phase I metabolites 
of U-51754 could be identified. In phS9 incubates, 10 metabolites were detected (A1–6, A9-11, A13). In these, 
N-demethyl-U-51754 formed the most abundant peak. In rat urine, seven metabolites were observed (A1, A6-8, 
A11-12, A14), with N-demethyl-hydroxy-U-51754 being the main metabolite. In urine samples, seven additional 
phase II metabolites were found (A15-21), five conjugated with glucuronic acid and two with sulphuric acid. 
Nine phase I metabolites of U-47931E could be identified. In this connection, N-demethyl-U-47931E was the 
most abundant peak in phS9 incubates and rat urine samples. In vitro, three metabolites were found (B1-3), and 
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in vitro all nine (B1-9) metabolites were detected. In the urine samples, four additional glucuronides were iden-
tified (B10-13).
The HR-MS data of methoxyacetylfentanyl indicated that the molecule could be cleaved between the pip-
eridine ring and the N-phenylacetamide moiety leading to the most abundant fragment ion of the phenyleth-
ylpiperidine. The phenethyl chain represented another characteristic fragment ion. The fragment ions of the 
unmodified or modified phenylethylpiperidine, phenethyl chain or methoxy-N-phenylacetamide were used 
(according to Fig. 3 and Table 3) for the spectra interpretation of methoxyacetylfentanyl metabolites. In total, 15 
phase I metabolites could be tentatively identified for methoxyacetylfentanyl. In phS9 incubates, 14 metabolites 
were detected (C1-9, C11-15) with O-demethyl-methoxyacetylfentanyl forming the most abundant peak. In rat 
urine, 11 metabolites were observed (C1-2, C4, C6-8, C10-12, C14-15), with hydroxy-methoxyacetylfentanyl 
being the main metabolite. In urine samples, six additional glucuronides were found (C16-21). One of them could 
be identified in phS9 as well.
eSi+ HR-MS/MS fragmentation of U-51754. U-51754 (PM at m/z 343.1336) was characterised by the 






























U-51754 C17H25ON2Cl2 343.1338 343.1336 −0.585 298.0758 −0.556 218.0134 −0.062 158.9763 −0.105 112.1124 2.559 5.62
A1 N-demethyl I- C16H23ON2Cl2 329.1181 329.1183 0.356 298.0757 −0.885 218.0133 −0.247 158.9760 −1.494 112.1118 −2.403 5.60
A2 N-demethyl II- C16H23ON2Cl2 329.1181 329.1177 −1.485 284.0609 1.905 203.9982 2.037 158.9767 3.892 98.0969 4.349 5.47
A3 N,N-bisdemethyl- C15H21ON2Cl2 315.1025 315.1020 −1.580 284.0602 −0.401 203.9977 −0.124 158.9765 1.649 98.0968 3.684 5.42
A4 N,N,N-tridemethyl- C14H20ON2Cl2 301.0868 301.0872 0.964 284.0604 0.268 203.9980 1.076 158.9763 0.130 98.0970 5.803 5.22
A5 Hydroxy I- C17H25O2N2Cl2 359.1287 359.1287 −0.221 314.0711 0.538 218.0134 −0.135 158.9762 −0.412 110.0969 4.204 4.75
A6 Hydroxy II- C17H25O2N2Cl2 359.1287 359.1286 −0.489 314.0707 −0.559 234.0082 −0.469 174.9711 −0.644 112.1123 1.972 4.15
A7 Dihydroxy I- C17H25O3N2Cl2 375.1236 375.1214 −6.067 330.0651 −2.170 234.0079 −1.840 174.9709 −1.863 110.0968 3.145 3.32
A8 Dihydroxy II- C17H25O3N2Cl2 375.1236 375.1536 3.050 330.0927 1.001 250.0273 2.964 190.9890 3.223 112.1124 2.924 5.21
A9 N-oxide- C17H25O2N2Cl2 359.1287 359.1292 1.130 298.0947 −1.128 218.0132 −0.855 158.9766 2.265 112.1124 2.860 5.52
A10 N-oxide-hydroxy- C17H25O3N2Cl2 375.1236 375.1236 −0.316 314.0710 0.416 218.0134 −0.108 158.9762 −0.338 110.0969 4.204 4.90
A11 N-demethyl-hydroxy I- C16H23O2N2Cl2 345.1131 345.1130 −0.424 314.0707 −0.083 218.0133 −0.103 158.9761 −1.083 110.0966 1.236 4.86










C15H21O2N2Cl2 331.0974 331.0976 0.410 314.0708 −0.413 219.9925 −0.690 174.9711 −0.434 112.1123 2.191 4.48
A15 hydroxy-glucuronide C23H33O8N2Cl2 535.1608 535.1611 0.471 359.1273 −1.253 314.0707 0.736 234.0082 −0.546 112.1123 1.996 4.58



























C15H20O5N2Cl2S 411.0542 411.0529 −5.071 331.0962 −4.097 300.0542 −2.954 219.9921 −1.624 112.1122 0.746 4.15
Table 1. Identification (ID), U-51754 and its metabolites as well as elemental composition, exact mass, 
accurate mass, characteristic product ions, mass errors, and retention time (RT) of the compounds detected 
in pS9 incubations and in rat urine after oral administration. Elemental composition and all given masses are 
protonated forms.
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3,4-dichlorophenyl-N-methylacetamide (m/z at 218.0134, C9H10ONCl2) and the N-methylcyclohexanamine (m/z 
at 112.1124, C7H14N) were other characteristic fragment ions. Low-abundant fragment ions at m/z 158.9763 and 
81.0707 were related to the 3,4-dichloro-1-methylbenzene and the cyclohexyl ring respectively.
N-demethyl-U-51754. According to Fig. 1, the fragmentation pattern of the most abundant metabolite, 
N-demethyl-U-51754 (A1, PM at m/z 329.1183), showed, as expected, an initial loss of methanamine forming 
the most abundant fragment ion at m/z 298.0757 followed by the cleavage at the amide nitrogen producing the 
fragment ion at m/z 218.0133, which belongs to the dichlorophenyl-N-methylacetamide part. Furthermore, the 
metabolite was identified by a fragmentation pattern similar to that of the parent substance, indicating loss of 
methyl at the amine moiety. N-demethyl-U-51754 formed two isomers in phS9 incubations, which could be 
separated chromatographically. Thus, the position of N-demethylation must be different. The spectrum of A2 
(EMS) represented fragment shifts due to the loss of a methyl group (−14.0156 u) at the fragments related to the 
dichlorophenyl-N-methylacetamide and the cyclohexyl-dichlorophenyl-N-methylacetamide.
Hydroxy-U-51754. The hydroxy metabolite A5 (PM at m/z 359.1287) was identified by the parent ion as 
well as the fragment ions at m/z 314.0711, representing the loss of dimethylamine at the cyclohexyl ring. The 
fragment ions at m/z 218.0134 and 158.9762 corresponded to an unaltered phenyl-N-methylacetamide. However, 
the presence of the fragment ions at m/z 79.0550 and 110.0969 indicated the loss of water after hydroxylation at 
the cyclohexyl ring. Taking these findings together, this spectrum might be the result of a monohydroxylation at 
the cyclohexyl ring. Regarding this PM and those of other hydroxylated metabolites, multiple peaks occurred in 
the chromatogram, which implicated sites of hydroxylation at the cyclohexyl ring. However, it was not possible to 
determine the exact position of hydroxylation and its relationship to different retention times. Regarding mono-
hydroxylation, several metabolites could be identified. The first peak with the PM of m/z 359.1287 was related to 
a hydroxylation that occurred at the benzyl ring or the methylene linker (A6). A6 was identified by the charac-
teristic fragment ions at m/z 81.0706 and 112.1123, indicating an unaltered cyclohexyl ring and thus excluding 
this as the site of hydroxylation. Additionally, no loss of water was observed after cleavage of the hydroxy group. 
However, the ions at m/z 174.9711 and 234.0082 with a mass shift of +15.9946 u (O) indicated a hydroxylation 




























U-47931E C15H22ON2Br 325.0909 325.0911 0.191 280.0332 0.069 199.9706 0.064 182.9440 0.230 126.1279 1.251 4.10
B1 N-demethyl- C14H20ON2Br 311.0753 311.0752 −0.392 280.0331 −0.095 199.9705 −0.061 182.9441 0.272 112.1124 3.325 3.98
B2 N,N-bisdemethyl- C13H18ON2Br 297.0596 297.0594 −0.919 280.0327 −1.551 199.9702 0.103 182.9437 −1.391 98.0969 4.346 3.89
B3 Hydroxy I- C15H22O2N2Br 341.0859 341.0858 −0.313 296.0278 −0.973 278.0174 −0.434 182.9439 −0.433 142.1226 −0.373 3.45
B4 Hydroxy II- C15H22O2N2Br 341.0859 341.0860 0.238 296.0280 −0.075 215.9654 −0.133 198.9388 −0.610 126.1226 0.737 4.38
B5 N-demethyl-hydroxy I- C14H20O2N2Br 327.0702 327.0704 0.434 296.0278 −0.933 278.0174 −0.027 182.9440 −0.4257 128.1071 0.619 3.30










C13H18O2N2Br 313.0546 313.0500 1.610 296.0283 0.718 215.9655 0.718 198.9388 −0.809 98.0970 5.462 4.14
B9 N-demethyl-dihydroxy- C14H20O3N2CBr 343.0651 343.0646 −1.738 312.0227 −0.899 231.9600 −1.527 214.9336 −1.070 112.1124 2.745 4.34
B10 Hydroxy-glucuronide C21H30O8N2Br 517.1179 517.1186 1.139 341.0863 1.022 296.0282 0.370 215.9655 0.049 126.1278 0.737 3.77











C19H26O8N2Br 489.0866 489.0866 −0.165 313.0544 −0.642 296.0283 0.718 215.9654 −0.199 198.9388 −0.643 3.58
Table 2. Identification (ID), U-47931E and its metabolites as well as elemental composition, exact mass, 
accurate mass, characteristic product ions, mass errors, and retention time (RT) of the compounds detected 
in pS9 incubations and in rat urine after oral administration. Elemental composition and all given masses are 
protonated forms.
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the benzyl ring or the methylene linker. The exact position of the hydroxy group could not be elucidated by the 
methods applied.
eSi+ HR-MS/MS fragmentation of U-47931E. U-47931E (PM of m/z 325.0911) showed a concise 
fragmentation pattern. The 4-bromobenzaldehyde moiety represented the most abundant fragment ion at m/z 
182.9940 (C7H5OBr). Loss of dimethylamine and the 4-bromobenzamide led to other characteristic fragment ions 
at m/z 280.0322 (C13H18ONBr) and 199.9706 (C7H7ONBr). Low-abundant fragment ions at m/z 81.0705 (C6H9) 
and 126.1279 (C8H16N) were related to the cyclohexyl ring and the dimethyl cyclohexanamine respectively.
N-demethyl-hydroxy-U-47931E and N,N-bisdemethyl-hydroxy-U-47931E. According to Fig. 2, 
the N-demethylated hydroxylated metabolite (B5, PM at m/z 327.0704) was identified by the fragment ion at m/z 
Figure 1. HR-MS/MS spectra of U-51754 and selected phase I metabolites. The spectra with proposed 
structures, retention times (RT), detected in rat urine (RU) and/or pooled human S9 fraction incubations 
(S9), and predominant fragmentation patterns of U-51754 and metabolites are arranged according to their 
presentation in the text.
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296.0278, showing a loss of the methylamine and the characteristic mass shift of a hydroxy group (+15.9946 u, 
O). Furthermore, the concise fragment ions such as 182.9440 and 199.9704 were also present in the parent spec-
trum, indicating an unaltered bromobenzamide part. The fragment ions at m/z 79.0550 and 278.0174 resulted 
from loss of water at the cyclohexyl ring. Taking these findings together, this spectrum seemed to be related 
to an N-demethylated metabolite with further monohydroxylation at the cyclohexyl ring. The same character-
istics were observed for the N,N-bisdemethylated hydroxylated metabolite (B7, PM at m/z 313.0544), which 
showed a similar fragmentation pattern to B5 except for the precursor ion. Thus, hydroxylation must occur at the 
cyclohexyl ring, too. Regarding hydroxylated metabolites, multiple peaks occurred in the chromatogram, impli-
cating multiple sites of hydroxylation at the cyclohexyl ring. Concerning the structure of the metabolite, it should 
be mentioned that the exact position of the hydroxy group in the cyclohexyl ring could not be deduced from the 
fragmentation pattern and with the analytical methods used here.
Additionally, after SPE, minor amounts of all hydroxylated metabolites could be detected, with hydroxylation 
occurring at the benzyl instead of the cyclohexyl ring (B4, B6, B8, EMS). All fragmentation patterns showed the 
characteristic mass shift due to the presence of a hydroxy group at fragments related to the bromobenzyl ring, 
indicating monohydroxylation at the aromatic system.
eSi+ HR-MS/MS fragmentation of methoxyacetylfentanyl. The HR-MS data of methoxyacetylfen-
tanyl (PM of m/z 353.2225) formed the most abundant fragment ion at m/z 188.1435 (C13H18N). The phenethyl 
chain represented another characteristic fragment at m/z 105.0704 (C8H9). More fragment ions in low abundance 
were observed in the spectrum The fragment ion at m/z 84.0811 represented the intact piperidine ring, whereas 
degradation of the piperidine ring led to the minor fragment ions at m/z 134.0966 (C9H12N), 146.0958 (C10H12N), 
Figure 2. HR-MS/MS spectra of U-47931E and selected phase I metabolites. The spectra with proposed 
structures, retention times (RT), detected in rat urine (RU) and/or pooled human S9 fraction incubations 
(S9), and predominant fragmentation patterns of U-47931E and metabolites are arranged according to their 
presentation in the text.
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206.1163 (C12H16O2N), and 232.1332 (C14H18O2N). Amide cleavage resulted in the fragment ion at m/z 166.0857 
(2-methoxy N-phenylacetamide, C9H12O2N). Another low-abundant characteristic fragment ion was derived 
from the 4-anilio-N-phenethyl-piperidine part (4-ANPP) of the molecule (281.2014, C19H25N2) and could not be 
Figure 3. HR-MS/MS spectra of methoxyacetylfentanyl and selected phase I metabolites. The spectra with 
proposed structures, retention times (RT), detected in rat urine (RU) and/or pooled human S9 fraction 
incubations (S9), and predominant fragmentation patterns of methoxyacetylfentanyl and metabolites are 
arranged according to their presentation in the text.
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observed in all metabolite spectra. In general, methoxyacetylfentanyl showed a fragmentation pattern according 
to previous published metabolism studies of methoxyacetylfentanyl and other 4-anilinopiperidine-type fentanyl 
analogues18,29,30.
O-demethyl-methoxyacetylfentanyl. The main metabolic pathway seemed to be O-demethylation (C6, 
PM of m/z 339.2068). According to Fig. 3, the MS2 spectrum showed the same characteristic fragment ions as the 
parent compound except for the mass of the parent compound showing a loss of a methyl group (−14.0156 u). As 
described above, the fragments of the phenylethylpiperidine, phenethyl chain or methoxy-N-phenylacetamide 
were used for identification. The fragment ion of the phenylethylpiperidine at m/z 188.1435 represented the 
unmodified part of the molecule. On the other hand, the methoxy-N-phenylacetamide showed loss of methyl 































ylfentanyl C22H29O2N2 353.2223 353.2225 0.272 188.1435 0.867 134.0966 1.267 105.0704 4.841 84.0811 4.232 4.69
C1 N-dealkyl- (Nor) C14H21O2N2 249.1597 249.1600 1.031 166.0864 1.128 106.0656 4.501 84.0816 9.953 3.07
C2 N-dealkyl-O-demethyl- C13H19O2N2 235.1441 235.1442 −0.600 152.0707 0.878 94.0657 5.665 81.0812 9.881 1.84










C19H25ON2 297.1961 297.1962 0.211 204.1385 1.053 121.0651 2.394 84.0815 8.749 4.41
C6 O-demethyl- C21H25O2N2 339.2067 339.2068 0.345 218.1177 0.739 188.1435 −0.447 134.0965 0.906 105.0704 5.185 4.31
C7 O-demethyl-hydroxy I- C21H25O3N2 355.2016 355.2020 1.033 235.1439 −0.705 204.1385 1.022 121.0651 2.509 84.0815 8.876 3.65
C8 O-demethyl-hydroxy II- C21H25O3N2 355.2016 355.2016 −0.056 337.1910 −0.133 204.1384 0.446 186.1272 −2.796 91.0548 5.897 3.94





C22H29O4N2 385.2121 385.2124 0.823 234.1488 −0.389 192.1019 −0.105 151.0756 1.330 119.0494 2.289 3.87
C11 Hydroxy I- C22H29O3N2 369.2172 369.2176 0.795 249.1598 0.089 204.1385 0.968 121.0651 2.270 84.0815 8.648 4.09
C12 Hydroxy II- C22H29O3N2 369.2172 369.2175 0.704 351.2068 0.322 204.1383 0.073 186.1272 −3.071 105.0703 4.436 4.38
C13 N-oxide I- C22H29O3N2 369.2172 369.2180 2.020 261.1598 0.136 189.1386 0.085 146.0965 0.170 105.0703 4.218 5.10
C14 N-oxide II- C22H29O3N2 369.2172 369.2178 1.382 261.1599 0.596 186.1279 0.786 158.0965 0.309 105.0703 4.366 5.22






C25H33O7N2 473.2282 473.2283 0.214 297.1963 0.540 188.1436 1.229 105.0705 4.800 3.06











C29H35O10N2 561.2442 561.2447 0.696 385.2124 0.681 234.1488 −0.331 151.0755 0.995 119.0493 0.979 3.31





C29H39O10N2 575.2599 575.2599 −0.089 399.2281 0.684 234.1491 0.881 192.1019 0.111 151.0755 0.757 3.73
Table 3. Identification (ID), methoxyacetylfentanyl and its metabolites as well as elemental composition, 
exact mass, accurate mass, characteristic product ions, mass errors, and retention time (RT) of the compounds 
detected in pS9 incubations and in rat urine after oral administration. Elemental composition and all given 
masses are protonated forms.
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Nor-methoxyacetylfentanyl. Compared with the parent compound, the nor-methoxyacetylfentanyl 
metabolite (N-dealkylated derivative, C1, PM at m/z 249.1600) exhibited only few fragment ions. However, this 
metabolite could be identified by characteristic fragment ions for the 2-methoxy N-phenylacetamide part of 
the molecule. Identification was carried out by the concise fragment ion at m/z 84.0816, related to the piperi-
dine ring, as well as the fragment ion at m/z 166.0864, indicating an unchanged 2-methoxy N-phenylacetamide. 
Furthermore, no fragment ions belonging to the phenylethylpiperidine part of the molecule could be detected, 
indicating a cleavage of the molecule between the phenethylchain and the piperidine nitrogen.
Hydroxy-methoxyacetylfentanyl. Regarding hydroxylation, several metabolites could be identified. Two 
monohydroxylated metabolites were found (C11, C12, PM at m/z 369.2179). C11 showed the characteristic frag-
ment ions of the phenylethylpiperidine part with a mass shift of oxygen (+15.9946 u, O) forming the fragment 
ions at m/z 121.0652 and 204.1387, indicating a hydroxylation at the phenethyl chain. Conversely, the hydroxy 
metabolite C12 (EMS) showed initial loss of water forming the fragment ion at m/z 351.2054. The fragment ion at 
m/z 204.1387 represented hydroxylation at the phenylethylpiperidine part. However, the absence of the fragment 
ion at m/z 121.0652 and the presence of a mass shift of oxygen at the fragment at m/z 84.0815 resulted in the 
fragment at m/z 100.0763 and indicated a modified piperidine ring. Thus, hydroxylation might have occurred at 
the piperidine ring. Two other metabolites with the same m/z ratio were detected at 5.25 min (C13, C14, EMS) 
and could not be identified as hydroxy metabolites. Both spectra showed similar fragment ions to the parent 
spectrum, representing cleavage of oxygen without loss of water. These facts exclude the piperidine ring as the 
site of hydroxylation. The aromatic systems are also unlikely to undergo loss of hydroxy groups. Furthermore, the 
fragment ions formed are in accordance with those already described by Steuer et al. for N-oxide metabolites31. 
Those metabolites eluted after the parent compound, which has been frequently described for N-oxides1,29,32. 
Thus, N-oxidation at the nitrogen of the piperidine ring is the likeliest metabolic step. Owing to the molecular 
structure, two diastereomers could be formed with probably minimally different chromatographic properties, 
resulting in two detectable peaks.
eSi+ HR-MS/MS for identification of the phase II metabolites based on MS/MS fragmentation. 
Most fragments in the spectra of the conjugates were also present in those of the corresponding phase I 
Figure 4. Metabolic pathways of U-51754 studied in rat urine (RU) and pooled human S9 fraction incubations 
(S9). Phase II metabolites: glucuronides (G), and sulfates (S). Numbering according to Table 1.
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metabolites and are not discussed here. As shown in Tables 1–3, all glucuronides eliminated dehydrated glucu-
ronic acid (−176.0321 u) and all sulphates dehydrated sulphuric acid (−79.9568 u). In total, seven corresponding 
phase II metabolites of U-51754 could be identified and four for U-47931E. Despite conjugate cleavage prior to 
extraction for some phase II metabolites (A19, B11, EMS), only trace amounts of the aglyca have been detected. 
However, the spectra of these metabolites showed characteristic fragment ions, so metabolite identification was 
possible. The aglycon of the hydroxy-glucuronide of U-47931E (B10, EMS) could not be identified in the urinary 
samples, possibly due to low stability. Nevertheless, reliable identification by characteristic fragment ions was pos-
sible for this metabolite. As described above, more than one isomer with similar MS2 spectra could be detected for 
all N-demethylated and hydroxylated metabolites of the U-substances. Caused by multiple sites of hydroxylation, 
more isomers could be formed after conjugation with glucuronic acid or sulphuric acid.
In total, six phase II metabolites of methoxyacetylfentanyl could be identified; all formed through conju-
gation of their corresponding phase I metabolite with glucuronic acid. For some phase II metabolites, frag-
ment ions still containing the corresponding conjugate helped to evaluate the position of the conjugate. The 
fragment ion at m/z 380.1704 represented the hydroxy-4-ANPP conjugated with glucuronic acid after loss of 
the hydroxyacetaldehyde and could be found in the spectrum of the hydroxy-glucuronide (C20, EMS) and 
the O-demethyl-hydroxy-glucuronide (C18, EMS). The fragmentation ion at m/z 410.1818 represented the 
metabolised 4-ANPP part conjugated with glucuronic acid and could be found in the MS2 spectrum of the 
O-demethylated hydroxy-methoxy-glucuronide (C19, EMS). Sulphates of methoxyacetylfentanyl could not be 
detected, probably as a consequence of the generally reduced formation of sulphate conjugates in rats30. In line 
with our results, sulphates were only sparsely detected in previous studies as well18.
Proposed metabolic pathways. The proposed metabolic pathways of U-51754 are shown in Fig. 4. The 
predominant pathway was single or multiple N-demethylation of the amine moiety (A1, A2, A3, A4) and hydrox-
ylation of the cyclohexyl ring (A5). Hydroxylation to the respective N-oxide (A9) was also observed, as well as 
further hydroxylation of this metabolite at the hexyl ring (A10). After N-demethylation, the metabolites under-
went further oxidation to the respective hydroxy derivates (A11, A13). Another metabolic pathway included 
hydroxylation of either the benzyl ring or the methylene linker, also combined with N-demethylations or further 
hydroxylation (A6, A7, A8, A12, A14). The main hydroxylated phase I metabolites underwent further glucuro-
nidation (A15, A16, A17, A19, A20) or sulphation (A18, A21).
Figure 5. Metabolic pathways of U-47931E studied in rat urine (RU) and pooled human S9 fraction 
incubations (S9). Phase II metabolites: glucuronides (G). Numbering according to Table 2.
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Figure 5 shows the proposed metabolic pathway of U-47931E. The main initial step in the metabolic pathways 
was N-demethylation (B1). Further metabolism steps were an additional N-demethylation (B2) or hydroxylation 
at the cyclohexyl ring (B5, B7) or the cyclophenyl ring (B6, B8). The N-demethylated hydroxy metabolite with 
hydroxylation at the aromatic system (B6) could be further hydroxylated (B9). Hydroxylation of the parent com-
pound could occur at either the cyclohexyl (B3) or the benzyl ring (B4), forming two different metabolic path-
ways. All phase I metabolites with hydroxylation at the benzyl ring were conjugated to glucuronic acid (B10, B11, 
B12, B13), except for the N-demethylated dihydroxylated metabolite. Interestingly, no conjugates were formed 
after hydroxylation at the cyclohexyl ring even if higher amounts of corresponding phase I metabolites were 
found. Contrary to U-51754, no sulphated metabolites could be observed.
Figure 6 shows the proposed metabolic pathways for methoxyacetylfentanyl. Five initial metabolic steps could 
be postulated. One metabolic pathway was the N-dealkylation (C1). After N-dealkylation, the nor-metabolite was 
O-demethylated further (C2). On the other hand, one initial metabolic step was the O-demethylation (C6) itself, 
which was followed by further alkyl, piperidine or aryl hydroxylation (C7, C8, C9) or underwent methylation 
after two-fold hydroxylation (C10). The third metabolic pathway included the amide hydrolysis to the 4-ANPP 
derivative (C3) followed by hydroxylation (C4, C5). One additional metabolic pathway was the hydroxylation 
of the parent compound at either the alkyl moiety (C11) or the piperidine ring (C12) followed by methylation 
after two-fold hydroxylation (C15). Furthermore, hydroxylation to the respective N-oxide (C13, C14) could be 
observed. Some hydroxylated metabolites were further conjugated to glucuronic acid (C16, C17, C18, C19, C20, 
C21), whereas sulphates could not be detected.
Discussion
The parent compounds U-51754 and U-47931E as well as methoxyacetylfentanyl showed only very low signal 
abundances in rat urine. Concerning other U-substances, comparable results were found in previous studies33. 
In the case of fentanyl, less than 8% is excreted unchanged and approximately 85% is eliminated metabolised 
in faeces and urine within 72 h34. It can be assumed that fentanyl analogues will show a comparable behav-
iour. Following the administration of isofentanyl and 3-methylfentanyl, Meyer et al. could not detect the parent 
drugs in urine either30. In other urinary metabolism studies, the parent compounds could be detected with high 
Figure 6. Metabolic pathways of methoxyacetylfentanyl studied in rat urine (RU), pooled human S9 fraction 
incubations (S9), pooled human hepatocytes (PHH)18 and/or various biological human samples (H)18. Phase II 
metabolites: glucuronides (G). Numbering according to Table 3.
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abundances35,36. However, since urinary excretion of parent compounds predominantly occurs via metabolites, it 
is essential to determine metabolites that can serve as targets for urine screening.
After administration of U-51754, the N-demethyl-hydroxy metabolite was the most abundant one in the urine 
specimens, which is a rough assessment considering possible differences in abundance in different MS types. In 
addition, the N,N-bisdemethylated and hydroxylated metabolite were abundant, likewise the monohydroxylated 
metabolite and N-demethyl-U-51754. All these metabolites showed a distinctively higher abundance compared 
with the parent compound. In line with our results, the N-demethylated metabolite provided abundant signal 
intensities for other U-substances as well in previous studies and, as a consequence, should be used as a target28,37. 
However, even the N-demethyl-hydroxy metabolite and the hydroxy metabolite might be suitable as targets. In 
contrast, conjugated metabolites only showed low signal abundance and could be excluded.
For U-47931E, the most abundant metabolites were the one- and two-fold N-demethylated metabolites with 
or without further hydroxylation and the hydroxy metabolite. However, all metabolites exhibited signal intensities 
lower than that of the parent compound. Nonetheless, the N-demethylated metabolite reached good detectability 
in human in vitro assays as well and might be preferentially used as an additional urinary marker. Conjugated 
metabolites were the least abundant metabolites and thus excluded as possible targets.
The alkyl hydroxy metabolite was the most abundant metabolite in rat urine samples after administration of 
methoxyacetylfentanyl, showing a much higher signal abundance than that of the parent compound. Hydroxy 
metabolites were found to be one of the main metabolites of different fentanyl analogues in other studies as well, 
but not yet for methoxyacetylfentanyl18,33. Furthermore, the nor-metabolite and the O-demethylated metabo-
lite were also abundant metabolites. In line with these results, the nor-metabolite has already been described as 
the main metabolite of many fentanyl analogs31,34. As far as humans are concerned, Mardal et al. observed the 
parent compound, together with the O-demethylated metabolite and the amide hydrolysis product 4-ANPP, as 
representing the highest signal intensities in different biological samples18. However, this result was obtained by 
studying different tissue and blood samples and only one urine sample. This fact could have affected the detect-
ability of different metabolites, as in our study. Furthermore, 4-ANPP was found to be a minor metabolite in 
other metabolism studies for other fentanyls38–40. Taking these findings together, the nor-metabolite and the 
O-demethylated metabolite might be the most suitable targets for urine screening approaches. Supporting this, 
the O-demethylated metabolite was also elucidated as the main metabolite for the structurally related fentanyl 
analogue Ocfentanil41. Conjugated metabolites showed only low signal abundance, turning out to be neglected 
as possible targets.
Owing to the lack of authentic human urine samples, incubations with phS9 incubations were performed in 
this study and compared with the metabolites formed by rats. Incubations with phS9 fraction are one alternative 
model to HLM or hepatocyte cell cultures for the assessment of toxicokinetic data.1,21,31,42. However, in vitro mod-
els are limited, running the risk of missing metabolites. As a comprehensive model, an animal25 might be used, 
but the potential of interspecies differences in enzyme activity has to be considered43,44. Well-established models 
for metabolism studies are rats. In accordance with previous studies, this animal model can be used for urinary 
identification of metabolites after oral administration and thus was used in this study23,24,45. A comparison of 
all metabolites formed in vivo and in vitro is shown in Table 4. In general, major phS9 metabolites were in good 
agreement with major rat urine metabolites for all NSOs tested and the same biotransformations were observed. 
Many deviations between phS9 and urine metabolites can be explained by the different time allowed for metab-
olism and the missing recirculation of metabolites in vitro compared with in vivo. This leads to fewer metabolites 
in vitro in general and a lower prevalence of second- or third-generation metabolites. This is in accordance with 
previous studies comparing in vitro and in vivo metabolism using rat urine and phS922. The low formation of 
phase II metabolites in phS9 incubations might be caused by the low formation of underlying phase I metabolites.
For U-51754, seven out of 14 phase I metabolites could be detected in rat urine and 10 out of 14 in phS9 
incubations. Only three metabolites were identical in both models. The different sites of hydroxylation were one 
of the main differences between both models, but the main metabolic steps such as single N-demethylation, 
hydroxylation, and single N-demethylation combined with hydroxylation were comparable for both models. As 
already mentioned, different hydroxylation sites might be a species-related difference. Phase II metabolites were 
only detected in rat urine.
In summary, for U-47931E, more metabolites could be detected in vivo than in vitro. Only three out of nine 
metabolites were found in phS9 incubates. In particular, the formation of multiple-step metabolites was more 
dominant in the in vivo system. Phase II metabolites were again only found in vivo. However, the most abundant 
metabolites were comparable in both models.
For methoxyacetylfentanyl, eleven out of 15 phase I metabolites were found in rat urine and 14 out of 15 in 
phS9. Ten metabolites were identical in both models. The alkyl hydroxylated 4-ANPP could only be observed 
in phS9 incubations as well as the O-demethylated metabolite with further aryl hydroxylation. In rat urine, six 
phase II metabolites were found, whereas in phS9 incubations only one glucuronide could be identified. This is in 
accordance with findings published by Richter et al.21. In summary, most metabolic steps, particularly the main 
reactions such as the N-dealkylation, O-demethylation, and hydroxylation, were comparable in both models.
In general, the results of this study are in good agreement with those concerning comparable compounds. 
Owing to the lack of data from further metabolism studies on U-51754 or U-47931E, the results of this study 
must be compared with data from U-47700 or other U-substances such as U-49900. In terms of N-demethylation 
as a major metabolic pathway for U-51754 and U-47931E, our results are in good agreement with data already 
published on the metabolism of U-47700 in human liver microsomes (HLM) and human case samples28,37,46,47. 
Compared with previous studies33,47, this is the first study detecting phase II metabolites in this class of substances. 
Only for AH-7921, a structurally related compound, a glucuronide has already been described48. Contrary to 
U-51754, no sulphated metabolites could be observed for U-47931E, but the main phase I pathways determined 








A1 N-demethyl I- + +
A2 N-demethyl II- +
A3 N,N-bisdemethyl- +
A4 N,N,N-tridemethyl- +
A5 Hydroxy I- +
A6 Hydroxy II- + +
A7 Dihydroxy I- +
A8 Dihydroxy II- +
A9 N-oxide- +
A10 N-oxide-hydroxy- +
A11 N-demethyl-hydroxy I- + +
A12 N-demethyl-hydroxy II- +
A13 N,N-bisdemethyl-hydroxy I- +









B1 N-demethyl- + +
B2 N,N-bisdemethyl- + +
B3 Hydroxy I- + +
B4 Hydroxy II- +
B5 N-demethyl-hydroxy I- +
B6 N-demethyl-hydroxy II- +
B7 N,N-bisdemethyl-hydroxy I- +







C1 N-dealkyl- (Nor) + + +
C2 N-dealkyl-O-demethyl- + +
C3 Amide hydrolyzed- + + +
C4 Amide hydrolyzed hydroxy I- + + + +
C5 Amide hydrolyzed hydroxy II- + + +
C6 O-demethyl- + + + +
C7 O-demethyl-hydroxy I- + + +
C8 O-demethyl-hydroxy II- + +
C9 O-demethyl-hydroxy III- +
C10 O-demethyl-hydroxy-methoxy- +
C11 Hydroxy I- + + + +
C12 Hydroxy II- + +
C13 N-oxide I- +
C14 N-oxide II- + +
C15 Hydroxy-methoxy- + +
C16 Amide hydrolysed hydroxy-glucuronide +
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for this substance were in accordance with our results for U-51754 or further studies on other U-substances33. In 
total, fewer metabolites of U-47931E were formed in comparison to U-51754.
In general, the findings concerning the formation of metabolites of methoxyacetylfentanyl showed, on the one 
hand, similarities to other fentanyl-analogue metabolism studies1,18, but, on the other, differences regarding the 
formation of dihydroxylated metabolites. N-dealkylation was already found to be a common metabolic reaction 
for other fentanyls49,50. Further, the formation of 4-ANPP has already been described as a metabolic pathway 
for many other fentanyl analogues51–53. Other initial metabolic steps such as O-demethylation and hydroxyla-
tion have been published for methoxyacetylfentanyl by Mardal et al. or in previous studies of other fentanyls as 
well18,31. However, Mardal et al. did not detect N-oxidation. In contrast, they found the dihydroxylated metab-
olite. Furthermore, they could distinguish between hydroxylation at the ethyl side chain and the phenyl ring of 
this moiety by means of mass spectrometry. These differences could be an effect of different settings of the mass 
spectrometry analysis used in that study.
conclusions
The major phase I and II metabolites of the three NSOs, U-51754, U-47931E, and methoxyacetylfentanyl, were 
tentatively identified in phS9 as well as in rat urine specimens after oral administration. Concerning U-51754 
and U-47931E, N-demethylation of the amine moiety and hydroxylation of the hexyl ring as well as combina-
tions thereof led to the most abundant metabolites. N-dealkylation to the nor-metabolite, O-demethylation, and 
hydroxylation at the alkyl part of the molecule were observed to be the most abundant metabolites of methoxy-
acetylfentanyl. These findings indicate that metabolites are essential urinary targets for detecting these NSOs and 
confirm their consumption, as most of the parent compounds could only be detected with minor abundance 
in rat urine. In general, the results of this study are in good agreement with those concerning comparable com-
pounds obtained from HLM incubations, human hepatocytes, and/or human cases.
Compliance with ethical standards. The authors declare that the experiments have been conducted in 
accordance with all applicable institutional, national, or international guidelines for care and use of rats.
Data Availability
Datasets generated during and/or analyzed during the current study are not publicly available but are available 
from the corresponding author on reasonable request.
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